Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors

Shinsuke Kato, Takao Shinozawa, Hiroaki Nagashige, Miyuki Nakamura, Yoshiya Asano, Miki Takikawa, Masako Kato, Akira Awaya, Asao Hirano, Eisaku Ohama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have produced a novel rat IgG2a monoclonal antibody against a stage-specific fetal brain glyco-protein of 68 kDa (FGP68), and succeeded in applying it to staining paraffin sections. To gain some insight into the pathobiological significance of this FGP68, this monoclonal antibody was used in immunohistochemical studies to compare the expression of FGP68 and Ki-67 antigen (MIB-1) in 235 primary brain tumors. Approximately half of the glioblastomas multiforme (GBMs) (44/75) and anaplastic astrocytomas (9/17) as well as some astrocytomas (5/30), medulloblastomas (2/14) and primitive neuroectodermal tumors (2/10) had tumor cells that expressed FGP68; however, pilocytic astrocytomas (0/7), oligodendrogliomas (0/15), ependymomas (0/6), schwannomas (0/21), meningiomas (0/22) and pituitary adenomas (0/18) did not express FGP68. The values of the MIB-1 labeling index were statistically higher in GBMs (0.005<P<0.01, Wilcoxon rank-sum test) and anaplastic astrocytomas (0.025<P<0.05) that expressed FGP68 than in those that did not. Normal brain tissue from 20 individuals aged 3-75 years was negative for FGP68 and MIB-1. We conclude that primary brain tumors express FGP68, one of the oncofetal proteins derived from fetal brain, and that FGP68 expression in certain brain tumor cells may depend, in part, on proliferation potential. Based on the possibility that the stage-specific FGP68 plays an important role in brain embryogenesis, some of FGP68-expressing tumor cells might phylogenetically revert to more primitive cells.

Original languageEnglish (US)
Pages (from-to)57-66
Number of pages10
JournalActa Neuropathologica
Volume104
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Brain Neoplasms
Glycoproteins
Monoclonal Antibodies
Brain
Proteins
Astrocytoma
Glioblastoma
Nonparametric Statistics
Ki-67 Antigen
Oligodendroglioma
Primitive Neuroectodermal Tumors
Ependymoma
Medulloblastoma
Neurilemmoma
Pituitary Neoplasms
Meningioma
Paraffin
Embryonic Development
Neoplasms
Staining and Labeling

Keywords

  • Fetal brain glycoprotein 68 kDa
  • Immunohistochemistry
  • MIB-1 (Ki-67 antigen)
  • Oncefetal protein
  • Primary brain tumor

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors. / Kato, Shinsuke; Shinozawa, Takao; Nagashige, Hiroaki; Nakamura, Miyuki; Asano, Yoshiya; Takikawa, Miki; Kato, Masako; Awaya, Akira; Hirano, Asao; Ohama, Eisaku.

In: Acta Neuropathologica, Vol. 104, No. 1, 2002, p. 57-66.

Research output: Contribution to journalArticle

Kato, S, Shinozawa, T, Nagashige, H, Nakamura, M, Asano, Y, Takikawa, M, Kato, M, Awaya, A, Hirano, A & Ohama, E 2002, 'Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors', Acta Neuropathologica, vol. 104, no. 1, pp. 57-66. https://doi.org/10.1007/s00401-002-0521-0
Kato, Shinsuke ; Shinozawa, Takao ; Nagashige, Hiroaki ; Nakamura, Miyuki ; Asano, Yoshiya ; Takikawa, Miki ; Kato, Masako ; Awaya, Akira ; Hirano, Asao ; Ohama, Eisaku. / Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors. In: Acta Neuropathologica. 2002 ; Vol. 104, No. 1. pp. 57-66.
@article{ede0fdf000904aaeafe8c63638e989c5,
title = "Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors",
abstract = "We have produced a novel rat IgG2a monoclonal antibody against a stage-specific fetal brain glyco-protein of 68 kDa (FGP68), and succeeded in applying it to staining paraffin sections. To gain some insight into the pathobiological significance of this FGP68, this monoclonal antibody was used in immunohistochemical studies to compare the expression of FGP68 and Ki-67 antigen (MIB-1) in 235 primary brain tumors. Approximately half of the glioblastomas multiforme (GBMs) (44/75) and anaplastic astrocytomas (9/17) as well as some astrocytomas (5/30), medulloblastomas (2/14) and primitive neuroectodermal tumors (2/10) had tumor cells that expressed FGP68; however, pilocytic astrocytomas (0/7), oligodendrogliomas (0/15), ependymomas (0/6), schwannomas (0/21), meningiomas (0/22) and pituitary adenomas (0/18) did not express FGP68. The values of the MIB-1 labeling index were statistically higher in GBMs (0.005<P<0.01, Wilcoxon rank-sum test) and anaplastic astrocytomas (0.025<P<0.05) that expressed FGP68 than in those that did not. Normal brain tissue from 20 individuals aged 3-75 years was negative for FGP68 and MIB-1. We conclude that primary brain tumors express FGP68, one of the oncofetal proteins derived from fetal brain, and that FGP68 expression in certain brain tumor cells may depend, in part, on proliferation potential. Based on the possibility that the stage-specific FGP68 plays an important role in brain embryogenesis, some of FGP68-expressing tumor cells might phylogenetically revert to more primitive cells.",
keywords = "Fetal brain glycoprotein 68 kDa, Immunohistochemistry, MIB-1 (Ki-67 antigen), Oncefetal protein, Primary brain tumor",
author = "Shinsuke Kato and Takao Shinozawa and Hiroaki Nagashige and Miyuki Nakamura and Yoshiya Asano and Miki Takikawa and Masako Kato and Akira Awaya and Asao Hirano and Eisaku Ohama",
year = "2002",
doi = "10.1007/s00401-002-0521-0",
language = "English (US)",
volume = "104",
pages = "57--66",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors

AU - Kato, Shinsuke

AU - Shinozawa, Takao

AU - Nagashige, Hiroaki

AU - Nakamura, Miyuki

AU - Asano, Yoshiya

AU - Takikawa, Miki

AU - Kato, Masako

AU - Awaya, Akira

AU - Hirano, Asao

AU - Ohama, Eisaku

PY - 2002

Y1 - 2002

N2 - We have produced a novel rat IgG2a monoclonal antibody against a stage-specific fetal brain glyco-protein of 68 kDa (FGP68), and succeeded in applying it to staining paraffin sections. To gain some insight into the pathobiological significance of this FGP68, this monoclonal antibody was used in immunohistochemical studies to compare the expression of FGP68 and Ki-67 antigen (MIB-1) in 235 primary brain tumors. Approximately half of the glioblastomas multiforme (GBMs) (44/75) and anaplastic astrocytomas (9/17) as well as some astrocytomas (5/30), medulloblastomas (2/14) and primitive neuroectodermal tumors (2/10) had tumor cells that expressed FGP68; however, pilocytic astrocytomas (0/7), oligodendrogliomas (0/15), ependymomas (0/6), schwannomas (0/21), meningiomas (0/22) and pituitary adenomas (0/18) did not express FGP68. The values of the MIB-1 labeling index were statistically higher in GBMs (0.005<P<0.01, Wilcoxon rank-sum test) and anaplastic astrocytomas (0.025<P<0.05) that expressed FGP68 than in those that did not. Normal brain tissue from 20 individuals aged 3-75 years was negative for FGP68 and MIB-1. We conclude that primary brain tumors express FGP68, one of the oncofetal proteins derived from fetal brain, and that FGP68 expression in certain brain tumor cells may depend, in part, on proliferation potential. Based on the possibility that the stage-specific FGP68 plays an important role in brain embryogenesis, some of FGP68-expressing tumor cells might phylogenetically revert to more primitive cells.

AB - We have produced a novel rat IgG2a monoclonal antibody against a stage-specific fetal brain glyco-protein of 68 kDa (FGP68), and succeeded in applying it to staining paraffin sections. To gain some insight into the pathobiological significance of this FGP68, this monoclonal antibody was used in immunohistochemical studies to compare the expression of FGP68 and Ki-67 antigen (MIB-1) in 235 primary brain tumors. Approximately half of the glioblastomas multiforme (GBMs) (44/75) and anaplastic astrocytomas (9/17) as well as some astrocytomas (5/30), medulloblastomas (2/14) and primitive neuroectodermal tumors (2/10) had tumor cells that expressed FGP68; however, pilocytic astrocytomas (0/7), oligodendrogliomas (0/15), ependymomas (0/6), schwannomas (0/21), meningiomas (0/22) and pituitary adenomas (0/18) did not express FGP68. The values of the MIB-1 labeling index were statistically higher in GBMs (0.005<P<0.01, Wilcoxon rank-sum test) and anaplastic astrocytomas (0.025<P<0.05) that expressed FGP68 than in those that did not. Normal brain tissue from 20 individuals aged 3-75 years was negative for FGP68 and MIB-1. We conclude that primary brain tumors express FGP68, one of the oncofetal proteins derived from fetal brain, and that FGP68 expression in certain brain tumor cells may depend, in part, on proliferation potential. Based on the possibility that the stage-specific FGP68 plays an important role in brain embryogenesis, some of FGP68-expressing tumor cells might phylogenetically revert to more primitive cells.

KW - Fetal brain glycoprotein 68 kDa

KW - Immunohistochemistry

KW - MIB-1 (Ki-67 antigen)

KW - Oncefetal protein

KW - Primary brain tumor

UR - http://www.scopus.com/inward/record.url?scp=0036941897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036941897&partnerID=8YFLogxK

U2 - 10.1007/s00401-002-0521-0

DO - 10.1007/s00401-002-0521-0

M3 - Article

C2 - 12070665

AN - SCOPUS:0036941897

VL - 104

SP - 57

EP - 66

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 1

ER -